Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Roche Media News
Get the latest updates from Roche Media News directly as they happen.
Follow now 292 followers
Latest posts
Last updated 2 days ago
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
2 days ago
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy...
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
4 days ago
New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets...
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions
5 days ago
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
9 days ago
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza...
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
12 days ago
OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without...
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
15 days ago
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options...
Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation
18 days ago
Switzerland’s most innovative research and development center underscores Roche’s long-term investment in...
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
24 days ago
New Phase II data show vast majority of patients experiencing no relapses...
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
about 1 month ago
With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce...
Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak
about 1 month ago
Roche is committed to supporting all those working to overcome the mpox...
European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)
about 2 months ago
Approval is based on data from two Phase III studies in branch...
Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
2 months ago
The acquisition of LumiraDx’s Point of Care technology received all required antitrust...